Modified factor VII

US6168789A · kind A · utility

Assignees

• ZYMOGENETICS INC. · US
• Novo Nordisk A/S · DK

Inventors

• Kathleen L. Berkner · Cleveland, US
• Lars Christian Petersen · Hørsholm, DK
• Charles E. Hart · Woodinville, US
• Ulla Hedner · Malmö, SE
• Claus Bregengaard · Hellerup, DK

Key dates

• Filing date: Nov 10, 1998
• Grant date: Jan 2, 2001
• Expiry date: Nov 10, 2018

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Y304/21021
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders, including platelet deposition, vascular thrombosis, ischemic reperfusion, acute closure of a coronary artery, vascular restenosis secondary to balloon angioplasty, endarterectomy, reductive atherectomy, stent placement, laser therapy or rotablation.